Meftal Painkiller Alert: Risk of Adverse Reaction

Government Advises Vigilance for Healthcare Users

The Indian Pharmacopoeia Commission (IPC) has issued a drug safety alert, urging healthcare professionals and patients to closely monitor adverse reactions associated with Meftal, a commonly used painkiller for menstrual cramps and rheumatoid arthritis.

Mefenamic acid, a painkiller, is prescribed for conditions such as rheumatoid arthritis, osteoarthritis, dysmenorrhea, mild to moderate pain, inflammation, fever, and dental pain.

According to the alert issued by the commission, a preliminary analysis of adverse drug reactions from the Pharmacovigilance Programme of India (PvPI) database identified instances of drug reactions associated with eosinophilia and systemic symptoms (DRESS) syndrome.

The alert, issued on November 30, advises healthcare professionals and patients to diligently monitor the potential occurrence of the mentioned adverse drug reaction (ADR) associated with the use of the suspected drug.

In case of encountering such a reaction, the alert recommends reporting the matter to the national coordination centre of the PvPI under the commission. This can be done by filling out a form on the website www.ipc.gov.in or through the Android mobile app ADR PvPI. Alternatively, individuals can contact the PvPI Helpline at 1800-180-3024.